Initial results of a phase 1 dose exploration and expansion study of xaluritamig plus abiraterone acetate (AA) in patients (pts) with mCRPC

Authors

• William Kelly

Publication/Presentation Date

5-2026

Volume

44

Issue

16

Published In/Presented At

DOI: 10.1200/JCO.2026.44.16_suppl.5070

Disciplines

Business Administration, Management, and Operations | Health and Medical Administration | Management Sciences and Quantitative Methods

Department(s)

Administration and Leadership

Document Type

Article